Skip to main content

Table 6 Comparative chart of clinical and economic results for treatment of patients with hepatitis C genotype 2/3

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Therapeutic schedule

Total costs

LY1

QALY2

Result

Peginterferon-alfa-2a + ribavirin

$Brz 13,120

15.21

14.57

peginterferon-alfa-2a is dominant

Peginterferon-alfa-2b + ribavirin

$Brz 17,465

15.11

14.32

 
  1. Notes: 1LYs – Life years; 2QALYs – Quality Adjusted Life Years.
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us